Jupiter Neurosciences Enters Definitive License Agreement With PharmAla For Its Patented, Non-Racemic MDMA Formulation ALA-002
Two developments have since materially changed the context for that structure. First, on July 20, 2026, PharmAla executed a definitive license agreement granting Jupiter Neurosciences, Inc. (NASDAQ:JUNS) exclusive U.S.
Jupiter Neuroscience made a deal to use PharmAla's special MDMA medicine in the United States. This is like getting permission to sell a new product, which could help the company grow if the medicine works and gets approved.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.